Login / Signup

Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.

Eiichi TanakaEisuke InoueAyako ShojiJonas NilssonChristos PapagiannopoulosDevender DhandaYuri YoshizawaMai AbeKumiko SakaEri SuganoNaohiro SugitaniMoeko OchiaiRei YamaguchiKatsunori IkariHisashi YamanakaMasayoshi Harigai
Published in: PloS one (2022)
ABA-1L demonstrated a favourable cost-effectiveness profile in RA patients, accruing savings for the Japanese healthcare payers.
Keyphrases